Abstract:BACKGROUND: Alzheimer's disease (AD) is a dementia, a neurodegenerative condition, and a protein-misfolding disease or proteinopathy, characterized by protein deposits, extracellular plaques and intracellular neurofibrillary tangles, which contain the AD's typical pathological proteins, abnormal β-amyloid and hyperphosphorylated tau, respectively, and are located predominantly in the cortex of the frontal, parietal, and temporal brain lobes. What is the role of molecular chaperones in AD? Data indicate that molecular chaperones, also known as Hsp, are involved in AD, probably displaying protective roles and/or acting as pathogenic factors as it occurs in chaperonopathies in which case AD would be suitable to chaperonotherapy. Hsp60, Hsp70, and Hsp90 can be augmented and overexpressed or diminished and downregulated in various situations in AD affected tissues and cells, indicating they are active during disease development and progression.QUESTION: What is the role of molecular chaperones in AD? Data indicate that molecular chaperones, also known as Hsp, are involved in AD, probably displaying protective roles and/or acting as pathogenic factors as it occurs in chaperonopathies in which case AD would be suitable to chaperonotherapy.OBJECTIVE: Investigate the role of Hsp in AD, focusing on Hsp60, Hsp70, and Hsp90.METHOD: Critical examination of published data.RESULTS: Hsp60, Hsp70, and Hsp90 can be augmented and overexpressed or diminished and downregulated in various situations in AD affected tissues and cells, indicating they are active during disease development and progression.CONCLUSION AND PERSPECTIVES: Notwithstanding that the roles and mechanisms of action of chaperones in AD are still incompletely understood, there is already enough evidence to encourage the development of therapeutic strategies targeting them, either to block their activity in case they promote disease progression or to boost their performance when they are protective. The latter is an example of positive chaperonotherapy, which also includes chaperone replacement via gene or protein administration. On the contrary, if a chaperone is found to help the disease, it has to be blocked or eliminated, which constitute modalities of negative chaperonotherapy.

Chaperone therapy for molecular pathology in lysosomal diseases

Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities

Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases

Chemical and pharmacological chaperones as new therapeutic agents

Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics

Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises

Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification

Second-Generation Pharmacological Chaperones: Beyond Inhibitors

Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases

Pharmacological Chaperones:Novel Therapeutic Strategies to Rescue Defective Protein Folding and Trafficking

Molecular Chaperones' Potential against Defective Proteostasis of Amyotrophic Lateral Sclerosis

Chemical chaperones: mechanisms of action and potential use

Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators

Alzheimer's Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy

[Pharmacological Chaperone Therapy for Fabry Disease]

The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts

The therapeutic potential of chemical chaperones in protein folding diseases

Chaperoning system: Intriguing target to modulate the expression of CFTR in cystic fibrosis

Neurodegenerative diseases associated with the disruption of proteostasis and their therapeutic strategies using chemical chaperones

Intracellular spatially-targeted chemical chaperones increase native state stability of mutant SOD1 barrel

5- C -Branched Deoxynojirimycin: Strategy for Designing a 1-Deoxynojirimycin-Based Pharmacological Chaperone with a Nanomolar Affinity for Pompe Disease